Verified factor-similar pair

IJR vs ISCB

These two ETFs meet the same FF6 US comparison criteria: US-listed equity ETFs, the same USD model basis, at least one material non-market factor, and 100% overlap in statistically significant material factor exposure.

SMB
Similarity score
89
Verified similar

The score combines exposure-level distance, factor-vector shape, market-beta closeness, and a small backtested relative-Sharpe term.

Quick Read

  • IJR has the higher backtested relative Sharpe (0.980 vs 0.793).
  • ISCB has the lower published fee (0.04% vs 0.06%).
  • ISCB is cheaper on dividend valuation (102 vs 110, where 100 is each fund's historical median).

These are screening signals, not a complete review of portfolio construction, turnover, taxes, or trading quality.

IJR

iShares Core S&P Small Cap ETF
SMB
Adj. R2
0.968
Rel. Sharpe
0.980
Mkt beta
0.99
AUM
US$96.8B
MER
0.06%
Valuation
110

ISCB

iShares Morningstar Small-Cap ETF
SMB
Adj. R2
0.972
Rel. Sharpe
0.793
Mkt beta
1.02
AUM
US$261M
MER
0.04%
Valuation
102

Factor Exposure Match

Blue bars compare raw factor beta magnitude. Green bars compare absolute t-stat strength. Dim bars indicate the t-stat is below 1.96.

SMB
IJR
+0.84
|t|
+36.0
ISCB
+0.74
|t|
+28.2
diff +0.09
HML
IJR
+0.20
|t|
+8.3
ISCB
+0.14
|t|
+5.3
diff +0.06
RMW
IJR
+0.13
|t|
+4.8
ISCB
+0.03
|t|
+1.0
diff +0.09
CMA
IJR
-0.02
|t|
-0.4
ISCB
-0.02
|t|
-0.4
diff +0.00
UMD
IJR
+0.03
|t|
+2.4
ISCB
-0.03
|t|
-1.7
diff +0.06

Why This Pair Matches

Exposure level
87
Exposure shape
100
Mkt beta diff
0.03
Rel. Sharpe diff
0.188

This comparison focuses on measured factor exposure. It does not compare holdings methodology, turnover, tax handling, or issuer process. Backtested relative Sharpe is a secondary signal rather than a stand-alone forecast. See methodology.

IJR fund page ISCB fund page US ETF Leaders US Universe
Important context

VerifiedBeta publishes educational ETF research, not personalized investment advice, portfolio management, or security recommendations. Funds that screen well here can still be unsuitable for your objectives, taxes, liquidity needs, or constraints. Review fund documents, methodology assumptions, and your own circumstances before acting. See the full disclaimer.